Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmonella phage cocktail
- Development stage
- Preclinical
- Lead developer
- Tbilisi Medical Academy
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Salmonella phage cocktail (also known as ESPCAL) is a liposome-encapsulated bacteriophage cocktail being developed for the treatment and prevention of Salmonella infections. Developed by the Tbilisi Medical Academy in collaboration with the George Eliava Institute of Bacteriophage, Microbiology and Virology, the therapy utilizes cationic liposomes to encapsulate lytic bacteriophages specific to Salmonella species. This encapsulation approach is designed to extend the in vivo lifespan of the phages, shield them from host immune defenses, improve stability against gastric acid, and enhance their ability to target intracellular pathogens. The project is currently in preclinical research.
- Other names
- ESPCAL liposome-encapsulated Salmonella phagesliposome-encapsulated Salmonella phages
02
Targets
Salmonella lipopolysaccharide O-antigen
Beyond the preview
Go deeper on salmonella phage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmonella phage cocktail.